Latest debt-to-equity ratio
SAB Biotherapeutics Debt-to-equity ratio
Direct answer
SAB Biotherapeutics's debt-to-equity ratio is 2.39%.
The verified market snapshot reports 2.39%.
Bullstory displays the reported value and does not estimate missing data.
Market data checked October 22, 2026.
Get free SAB Biotherapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Debt-to-equity ratio
- 2.39%